Table 3. Meta-analysis results of the associations of increased SOX9 expression with clinicopathological parameters.

Clinicopathological parameter	Ref	Overall OR (95% CI)	Heterogeneity test (I2, P-value)
Gender (male vs female)	[9, 14, 16, 18, 19, 32, 38, 39]	0.99 (0.85–1.15)	0.0%, 0.439
Tumor Differentiation (poor VS well)	[9, 18, 19, 32, 38, 39]	1.13 (0.93–1.39)	59.2%, 0.031
Tumor Size (T3-4 vs T1-2)	[9, 14, 16, 18, 19, 32, 38, 39]	1.58 (1.31–1.91)	81.3%, 0.000
Lymph Node Metastasis (yes vs no)	[9, 18, 19, 32, 39]	1.61 (1.30–1.99)	84.9%, 0.000
Distant Metastasis (yes vs no)	[9, 14, 16, 19, 32, 39]	1.53 (1.25–1.87)	27.3%, 0.230
Clinical Stage (III-IV vs I-II)	[9, 14, 16, 18, 19, 32, 39]	1.68 (1.33–2.12)	90.4%, 0.000